Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426729 | 1.00 | KMT2A (0.57) | KMT2AGID4ATML3MBTL1SMN1; SMN2 | |
| SCHEMBL3425556 | 1.00 | KMT2A (0.57) | KMT2AGID4ATML3MBTL1SMN1; SMN2 | |
| SCHEMBL3425884 | 0.97 | KMT2A (0.61) | KMT2AGID4ATML3MBTL1SMN1; SMN2 | |
| SCHEMBL3423853 | 0.97 | KMT2A (0.61) | KMT2AGID4ATML3MBTL1SMN1; SMN2 | |
| SCHEMBL3423855 | 0.97 | KMT2A (0.61) | KMT2AGID4ATML3MBTL1SMN1; SMN2 | |
| SCHEMBL3423798 | 0.87 | ATM (0.68) | KMT2AATML3MBTL1SMN1; SMN2MAOB | |
| SCHEMBL3425487 | 0.87 | ATM (0.68) | KMT2AATML3MBTL1SMN1; SMN2MAOB | |
| SCHEMBL3423796 | 0.87 | ATM (0.68) | KMT2AATML3MBTL1SMN1; SMN2MAOB | |
| SCHEMBL3424000 | 0.84 | ATM (0.73) | KMT2AATML3MBTL1SMN1; SMN2MAOB | |
| SCHEMBL3427290 | 0.84 | ATM (0.73) | KMT2AATML3MBTL1SMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | claimed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | HTR7, MAOB, CYP2A7 | KMT2A 3724/4885GID4 3016/4885ATM 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.